此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Prospective Registry of Exposure to Gepotidacin (PREG)

2026年9月29日 更新者:GlaxoSmithKline

Prospective Registry of Exposure to Gepotidacin (PREG): a Prospective Registry of Women and Their Offspring Exposed to Gepotidacin During Pregnancy

The purpose of this study is to monitor pregnancies exposed to gepotidacin and to evaluate possible teratogenic effects or birthweight-lowering effects of this medication relative to the primary outcomes of major congenital malformations (MCMs) and small for gestational age (SGA), as well as to evaluate secondary maternal, fetal, and infant outcomes.

研究概览

地位

尚未招聘

条件

研究类型

观察性的

注册 (估计的)

614

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

15年 至 50年 (孩子、成人)

接受健康志愿者

不

有资格学习的性别

女性

取样方法

非概率样本

研究人群

Pregnant participants with uncomplicated urinary tract infection who are exposed to gepotidacin or standard-of-care antibiotics during the relevant exposure window.

描述

Inclusion Criteria:

For Both cohorts:

  • Participants with aged 15 to 50 years
  • United States resident
  • Currently pregnant
  • Participants personally signed and dated informed consent document or, upon waiver of written consent by the relevant Institutional review board (IRB), verbal consent indicating that the participant (or a legally acceptable representative) has been informed of all pertinent aspects of the study
  • Authorization and contact information for the reporter (e.g., participant, maternal/infant Health care provider (HCP), prescriber) to allow for follow-up

Exposed cohort:

• Exposed to gepotidacin at any time during pregnancy or the relevant exposure window

Comparator cohort:

  • Diagnosis of and treatment for uUTI at any time during pregnancy or the relevant comparator product exposure window
  • Exposed to one or more American College of Obstetricians and Gynecologists (ACOG)-recommended treatments for acute cystitis at any time during pregnancy or the relevant comparator product exposure window

Exclusion Criteria:

For Both cohorts:

• Diagnosis of known MCMs for the index pregnancy prior to enrollment

Exposed cohort:

• None

Comparator cohort:

• Exposure to gepotidacin at the time of enrollment

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Exposed cohort

Pregnant participants with uncomplicated urinary tract infection (uUTI) who are exposed to gepotidacin during the relevant exposure window

Not Applicable since Observational Study

其他名称:
  • 观察性研究
Comparator cohort

Pregnant participants with uncomplicated urinary tract infection (uUTI) who are exposed to standard-of-care antibiotics during the relevant exposure window

Not Applicable since Observational Study

其他名称:
  • 观察性研究

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of infants with major congenital malformations (MCMs)
大体时间:At pregnancy outcome, with follow-up through 12 months after delivery

An abnormality of body structure or function that is present at birth, is of prenatal origin (i.e., birth defect), has significant medical, social, or cosmetic consequences for the affected individual, and typically requires medical intervention.

At pregnancy outcome, with follow-up through 12 months after delivery
Number of infants with small-for-gestational-age births (SGA)
大体时间:At live birth

A newborn infant whose birth weight is less than (<) 10th percentile for sex and gestational age using standard growth charts for full- and preterm live-born infants.

At live birth

次要结果测量

结果测量
措施说明
大体时间
Number of infants with minor congenital malformations
大体时间:At live Birth, with follow-up up through 12 months of age

An anomaly or abnormality of body structure that is present at birth, is of prenatal origin (i.e., birth defect), poses no significant health problem in the neonatal period, and tends to have limited social or cosmetic consequences for the affected individual.

At live Birth, with follow-up up through 12 months of age
Number of participants (pregnant women) with pregnancy termination
大体时间:From date of conception (DOC) to <20 gestational weeks

A voluntary fetal loss or interruption of pregnancy that occurs for any reason, including but not limited to for the preservation of maternal health or because of fetal abnormalities.

From date of conception (DOC) to <20 gestational weeks
Number of participants (pregnant women) with spontaneous abortions (SAB)
大体时间:From date of conception (DOC) to <20 gestational weeks

An involuntary fetal loss or the expulsion of the products of conception occurring at less than (<) 20 gestational weeks.

From date of conception (DOC) to <20 gestational weeks
Number of participants (pregnant women) with stillbirths
大体时间:From 20 weeks' gestation to pregnancy outcome

Stillbirth is defined by the American College of Obstetricians and Gynecologists (ACOG), an involuntary fetal loss occurring at greater than or equal to (>=) 20 weeks of gestation, or, if gestational age is unknown, a fetus weighing >=350 grams.

From 20 weeks' gestation to pregnancy outcome
Number of participants (pregnant women) with preeclampsia
大体时间:From 20 weeks' gestation to pregnancy outcome

Preeclampsia is disorder of pregnancy associated with new-onset hypertension, which occurs most often after 20 weeks of gestation and frequently near term, and proteinuria, or, in the absence of proteinuria, it is defined as new-onset hypertension with the new onset of any of the following: Thrombocytopenia: platelet count <100,000/milliliter (mL). Renal insufficiency: serum creatinine concentrations >1.1 milligram per deciliter (mg/dL) or a doubling of the serum creatinine concentration in the absence of other renal disease. Impaired liver function: elevated blood concentrations of liver transaminases to twice the normal concentration. Pulmonary edema. New-onset headache unresponsive to medication and not accounted for by alternative diagnoses or visual symptoms

From 20 weeks' gestation to pregnancy outcome
Number of participants (pregnant women) with eclampsia
大体时间:From 20 weeks' gestation to pregnancy outcome

New-onset tonic-clonic, focal, or multifocal seizures in the absence of other causative conditions such as epilepsy, cerebral arterial ischemia and infarction, intracranial hemorrhage, or drug use.

From 20 weeks' gestation to pregnancy outcome
Number of participants (pregnant women) with gestational hypertension
大体时间:From 20 weeks' gestation to pregnancy outcome

Blood pressure greater than 140 millimeter of mercury (mmHg) systolic or 90 mmHg diastolic on 2 separate occasions at least 4 hours apart after 20 weeks of pregnancy when previous blood pressure was normal.

From 20 weeks' gestation to pregnancy outcome
Number of participants (pregnant women) with gestational diabetes
大体时间:At pregnancy outcome

Any degree of glucose intolerance with onset or first recognition during pregnancy.

At pregnancy outcome
Number of participants (pregnant women) with preterm births
大体时间:At live birth, if occurring before 37 gestational weeks

Preterm birth is defined as a live birth occurring at <37 gestational weeks.

At live birth, if occurring before 37 gestational weeks
Number of infants with postnatal growth deficiency
大体时间:At 4 and 12 months of infant age

Weight, length, or head circumference in <10th percentile for sex and chronological age using standard growth charts

At 4 and 12 months of infant age
Number of infants with developmental delay
大体时间:At 4 and 12 months of infant age

Failure to achieve the developmental milestones for chronological age, as defined by the Centers for Disease Control and Prevention.

At 4 and 12 months of infant age

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:GSK Clinical Trials、GlaxoSmithKline

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月30日

初级完成 (估计的)

2032年8月19日

研究完成 (估计的)

2032年8月19日

研究注册日期

首次提交

2026年9月11日

首先提交符合 QC 标准的

2026年9月29日

首次发布 (实际的)

2026年9月30日

研究记录更新

最后更新发布 (实际的)

2026年9月30日

上次提交的符合 QC 标准的更新

2026年9月29日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅